Diapro Adverse Reactions

Potentially life-threatening effects: All hypoglycemic agents have the potential to cause severe hypoglycemia and may cause severe brain damage or death. Gliclazide used in standard dose is less likely than Glyburide to cause hypoglycemia. Hypoglycemia may be precipitated by concurrent conditions such as hepatic and renal disease, malnutrition, anorexia, senility, alcohol intoxication or adrenal and pituitary insufficiency.
Severe or irreversible adverse effects: Approximately 2% of patients have been withdrawn from therapy because of adverse reactions, namely hypoglycemia (overdose effect), gastrointestinal disturbances and dermatological reactions.
Symptomatic adverse effects: Side effects of Gliclazide treatment are similar to those of other sulfonylureas. Headache, gastrointestinal upsets, nausea, and dizziness have been reported and skin reactions, including rash, pruritus, erythema and bullous eruptions may occur. Abnormalities of liver function (e.g. elevations of AST, ALT, and/or alkaline phosphatase) may occur. Hepatitis has been rarely reported. Treatment should be discontinued if cholestatic jaundice occurs.
Hematological effects including anemia, leucopenia, and thrombocytopenia have been reported.